AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Myriad Genetics Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) filed an 8-K disclosing its ninth one-month extension to complete a business combination. The Board moved the deadline, known as the “Business Combination Period,� from 5 Aug 2025 to 5 Sep 2025.

To effect the extension, sponsor CGC II Sponsor LLC will advance $250,000 under an unsecured promissory note that permits borrowings up to $2.4 million. The funds will be deposited into the IPO trust account as required by the company’s amended memorandum and articles.

This is the 9th of 12 permissible monthly extensions; no additional financial results, target identification, or other material transactions were reported.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) ha depositato un modulo 8-K comunicando la nona proroga di un mese per completare una fusione aziendale. Il Consiglio ha spostato la scadenza, nota come “Periodo di Combinazione Aziendale,� dal 5 agosto 2025 al 5 settembre 2025.

Per attuare la proroga, lo sponsor CGC II Sponsor LLC anticiperà 250.000 $ tramite una nota di debito non garantita che consente prestiti fino a 2,4 milioni di $. I fondi saranno depositati nel conto fiduciario dell’IPO come previsto dal memorandum e dallo statuto modificati della società.

Questa è la 9ª di 12 proroghe mensili consentite; non sono stati riportati risultati finanziari aggiuntivi, identificazione di nuovi obiettivi o altre transazioni rilevanti.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) presentó un formulario 8-K revelando su novena prórroga de un mes para completar una combinación de negocios. La Junta movió la fecha límite, conocida como el “Período de Combinación de Negocios,� del 5 de agosto de 2025 al 5 de septiembre de 2025.

Para efectuar la prórroga, el patrocinador CGC II Sponsor LLC adelantará 250,000 $ mediante una nota promisoria no garantizada que permite préstamos de hasta 2.4 millones de $. Los fondos se depositarán en la cuenta fiduciaria de la oferta pública inicial según lo requerido por el memorando y los estatutos enmendados de la compañía.

Esta es la 9ª de 12 prórrogas mensuales permitidas; no se reportaron resultados financieros adicionales, identificación de objetivos ni otras transacciones materiales.

Cartesian Growth Corporation II (나스ë‹�: RENE/RENEU/RENEW)ëŠ� 사업 ê²°í•© 완료ë¥� 위한 아홉 번째 1개월 연장 소ì‹ì� 8-K ë³´ê³ ì„œì— ê³µê°œí–ˆìŠµë‹ˆë‹¤. ì´ì‚¬íšŒëŠ” ‘사ì—� ê²°í•© 기간â€� 마ê°ì¼ì„ 2025ë…� 8ì›� 5ì¼ì—ì„� 2025ë…� 9ì›� 5ì¼ë¡œ 연기했습니다.

연장ì� 위해 스í°ì„œì¸ CGC II Sponsor LLCëŠ� 최대 240ë§� 달러까지 ëŒ€ì¶œì´ ê°€ëŠ¥í•œ 무담ë³� 약ì†ì–´ìŒìœ¼ë¡œ 25ë§� 달러ë¥� 선지급할 예정입니ë‹�. ì� ìžê¸ˆì€ 회사ì� 수정ë� ì •ê´€ ë°� ê°ì„œì—� ë”°ë¼ IPO ì‹ íƒ ê³„ì¢Œì—� 입금ë©ë‹ˆë‹�.

ì´ë²ˆì� 허용ë� 12íš� ì¤� 9번째 월별 연장입니ë‹�; 추가 재무 ê²°ê³¼, 목표 ì‹ë³„ ë˜ëŠ” 기타 중요í•� 거래ëŠ� ë³´ê³ ë˜ì§€ 않았습니ë‹�.

Cartesian Growth Corporation II (Nasdaq : RENE/RENEU/RENEW) a déposé un formulaire 8-K révélant sa neuvième prolongation d’un mois pour finaliser une opération de fusion. Le conseil d’administration a repoussé la date limite, appelée « Période de Combinaison d’Entreprise », du 5 août 2025 au 5 septembre 2025.

Pour effectuer cette prolongation, le sponsor CGC II Sponsor LLC avancera 250 000 $ via un billet à ordre non garanti autorisant des emprunts jusqu’� 2,4 millions de $. Les fonds seront déposés sur le compte fiduciaire de l’introduction en bourse, conformément au mémorandum et aux statuts modifiés de la société.

C’est la 9e des 12 prolongations mensuelles autorisées ; aucun résultat financier supplémentaire, identification de cible ou autre transaction importante n’a été signalé.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) hat in einem 8-K-Bericht seine neunte einmonatige Verlängerung zur Durchführung einer Unternehmenszusammenführung bekanntgegeben. Der Vorstand verschob die Frist, bekannt als „Business Combination Period�, vom 5. August 2025 auf den 5. September 2025.

Zur Umsetzung der Verlängerung wird der Sponsor CGC II Sponsor LLC 250.000 $ mittels eines ungesicherten Schuldscheindarlehens vorstrecken, das Kreditaufnahmen bis zu 2,4 Millionen $ erlaubt. Die Mittel werden auf das IPO-Treuhandkonto eingezahlt, wie es im geänderten Gesellschaftsvertrag vorgesehen ist.

Dies ist die 9. von 12 zulässigen monatlichen Verlängerungen; es wurden keine zusätzlichen Finanzergebnisse, Zielidentifikationen oder sonstige wesentliche Transaktionen gemeldet.

Positive
  • Sponsor advances $250,000 to fund the trust, signaling ongoing financial support.
  • Trust account remains intact, preserving redemption value for public shareholders.
Negative
  • Ninth extension highlights continued inability to secure a merger target, increasing deal uncertainty.
  • Additional borrowing under the $2.4 million note raises leverage ahead of any future transaction.

Insights

TL;DR � Ninth extension keeps SPAC alive but signals difficulty closing a deal; sponsor support limits immediate redemption risk.

Another one-month extension to 5 Sep 2025 indicates CGC II has yet to secure a definitive merger agreement. The sponsor’s $250k deposit demonstrates continued financial backing, protecting the trust value and meeting charter requirements. However, with only three monthly extensions left, time pressure rises and potential targets gain negotiating leverage. Overall impact is neutral: cash safety maintained, but strategic uncertainty persists.

TL;DR � Repeated deadline pushes heighten execution risk; growing sponsor loan increases leverage against future proceeds.

The ninth consecutive extension underscores prolonged deal sourcing challenges, raising the probability of liquidation or shareholder fatigue. Each draw on the unsecured note—now at least $250k—adds liabilities senior to ordinary shareholders upon closing. With only three extensions remaining, investors should monitor note balance growth and any shift in sponsor commitment. From a risk viewpoint, the filing leans negative because timeline slippage and incremental debt can erode eventual transaction economics.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) ha depositato un modulo 8-K comunicando la nona proroga di un mese per completare una fusione aziendale. Il Consiglio ha spostato la scadenza, nota come “Periodo di Combinazione Aziendale,� dal 5 agosto 2025 al 5 settembre 2025.

Per attuare la proroga, lo sponsor CGC II Sponsor LLC anticiperà 250.000 $ tramite una nota di debito non garantita che consente prestiti fino a 2,4 milioni di $. I fondi saranno depositati nel conto fiduciario dell’IPO come previsto dal memorandum e dallo statuto modificati della società.

Questa è la 9ª di 12 proroghe mensili consentite; non sono stati riportati risultati finanziari aggiuntivi, identificazione di nuovi obiettivi o altre transazioni rilevanti.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) presentó un formulario 8-K revelando su novena prórroga de un mes para completar una combinación de negocios. La Junta movió la fecha límite, conocida como el “Período de Combinación de Negocios,� del 5 de agosto de 2025 al 5 de septiembre de 2025.

Para efectuar la prórroga, el patrocinador CGC II Sponsor LLC adelantará 250,000 $ mediante una nota promisoria no garantizada que permite préstamos de hasta 2.4 millones de $. Los fondos se depositarán en la cuenta fiduciaria de la oferta pública inicial según lo requerido por el memorando y los estatutos enmendados de la compañía.

Esta es la 9ª de 12 prórrogas mensuales permitidas; no se reportaron resultados financieros adicionales, identificación de objetivos ni otras transacciones materiales.

Cartesian Growth Corporation II (나스ë‹�: RENE/RENEU/RENEW)ëŠ� 사업 ê²°í•© 완료ë¥� 위한 아홉 번째 1개월 연장 소ì‹ì� 8-K ë³´ê³ ì„œì— ê³µê°œí–ˆìŠµë‹ˆë‹¤. ì´ì‚¬íšŒëŠ” ‘사ì—� ê²°í•© 기간â€� 마ê°ì¼ì„ 2025ë…� 8ì›� 5ì¼ì—ì„� 2025ë…� 9ì›� 5ì¼ë¡œ 연기했습니다.

연장ì� 위해 스í°ì„œì¸ CGC II Sponsor LLCëŠ� 최대 240ë§� 달러까지 ëŒ€ì¶œì´ ê°€ëŠ¥í•œ 무담ë³� 약ì†ì–´ìŒìœ¼ë¡œ 25ë§� 달러ë¥� 선지급할 예정입니ë‹�. ì� ìžê¸ˆì€ 회사ì� 수정ë� ì •ê´€ ë°� ê°ì„œì—� ë”°ë¼ IPO ì‹ íƒ ê³„ì¢Œì—� 입금ë©ë‹ˆë‹�.

ì´ë²ˆì� 허용ë� 12íš� ì¤� 9번째 월별 연장입니ë‹�; 추가 재무 ê²°ê³¼, 목표 ì‹ë³„ ë˜ëŠ” 기타 중요í•� 거래ëŠ� ë³´ê³ ë˜ì§€ 않았습니ë‹�.

Cartesian Growth Corporation II (Nasdaq : RENE/RENEU/RENEW) a déposé un formulaire 8-K révélant sa neuvième prolongation d’un mois pour finaliser une opération de fusion. Le conseil d’administration a repoussé la date limite, appelée « Période de Combinaison d’Entreprise », du 5 août 2025 au 5 septembre 2025.

Pour effectuer cette prolongation, le sponsor CGC II Sponsor LLC avancera 250 000 $ via un billet à ordre non garanti autorisant des emprunts jusqu’� 2,4 millions de $. Les fonds seront déposés sur le compte fiduciaire de l’introduction en bourse, conformément au mémorandum et aux statuts modifiés de la société.

C’est la 9e des 12 prolongations mensuelles autorisées ; aucun résultat financier supplémentaire, identification de cible ou autre transaction importante n’a été signalé.

Cartesian Growth Corporation II (Nasdaq: RENE/RENEU/RENEW) hat in einem 8-K-Bericht seine neunte einmonatige Verlängerung zur Durchführung einer Unternehmenszusammenführung bekanntgegeben. Der Vorstand verschob die Frist, bekannt als „Business Combination Period�, vom 5. August 2025 auf den 5. September 2025.

Zur Umsetzung der Verlängerung wird der Sponsor CGC II Sponsor LLC 250.000 $ mittels eines ungesicherten Schuldscheindarlehens vorstrecken, das Kreditaufnahmen bis zu 2,4 Millionen $ erlaubt. Die Mittel werden auf das IPO-Treuhandkonto eingezahlt, wie es im geänderten Gesellschaftsvertrag vorgesehen ist.

Dies ist die 9. von 12 zulässigen monatlichen Verlängerungen; es wurden keine zusätzlichen Finanzergebnisse, Zielidentifikationen oder sonstige wesentliche Transaktionen gemeldet.

0000899923false00008999232025-08-052025-08-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  August 5, 2025
 
 
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware 0-26642 87-0494517
(State or other jurisdiction of
incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
 
322 North 2200 West
Salt Lake City, Utah 84116
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class Trading
Symbol(s)
 Name of each exchange on which registered
Common Stock, $0.01 par value MYGN Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



ITEM 2.02    Results of Operations and Financial Condition.
On August 5, 2025 Myriad Genetics, Inc. announced its financial results for the three months ended June 30, 2025.  The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in Exhibit 99.1 to this Current Report on Form 8-K regarding these forward-looking statements.




ITEM 9.01    Financial Statements and Exhibits.

Exhibit
Number
 Description
   
99.1 
Earnings release dated August 5, 2025 for the three months ended June 30, 2025.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

The exhibit(s) may contain hypertext links to information on our website or other parties’ websites. The information on our website and other parties’ websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Current Report on Form 8-K.
Limitation on Incorporation by Reference. In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
MYRIAD GENETICS, INC.
Date: August 5, 2025By:/s/ Scott J. Leffler
Scott J. Leffler
Chief Financial Officer



FAQ

Why did RENE/RENEW file this Form 8-K?

The company disclosed approval of its ninth one-month extension to complete a business combination and the related $250,000 sponsor deposit.

What is the new business-combination deadline for Cartesian Growth Corporation II?

The deadline was extended to September 5, 2025.

How much money is being added to the trust account?

$250,000 will be deposited by the sponsor under an unsecured promissory note.

How many extensions remain under the Articles?

Three one-month extensions remain; this was the 9th of 12 allowable extensions.

Does the filing mention any merger target or financial results?

No. The 8-K reports only the extension and related funding; no target or earnings data were provided.
Myriad Genetics

NASDAQ:MYGN

MYGN Rankings

MYGN Latest News

MYGN Latest SEC Filings

MYGN Stock Data

360.41M
89.18M
2.77%
103.48%
8.2%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
United States
SALT LAKE CITY